Advancing Allogeneic iNKT Therapy: MiNK CEO Jennifer Buell on AGENT-797 Results
In this OncoDaily episode, Dr. Amalya Sargsyan, Medical Oncologist and Vice President for Research & Intelligence at OncoDaily, speaks with Dr. Jennifer Buell, President & CEO of MiNK Therapeutics, a pioneer in allogeneic invariant natural killer T-cell (iNKT) therapies. 🎙️ WHAT YOU’LL LEARN IN THIS INTERVIEW ✅ What invariant natural killer T cells (iNKTs) are, and why they are different from NK cells or CAR-T cells ✅ How MiNK Therapeutics produces scalable, off-the-shelf, chemotherapy-free iNKT therapies (Agent-797) ✅ Why iNKT cells can survive and function in a hostile tumor microenvironme…